Denecimig  (Synonyms: Mim8)

Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

F9 & F10

Denecimig efficiently enhances FX activation by localizing FIXa and FX to phospholipid surfaces, with its anti-FIXa arm alone increasing FIXa proteolytic activity 15,000-fold, and binds FIXa and FX with micromolar dissociation constants^[1].
Denecimig (0.1-1000 nM) normalizes thrombin generation in congenital HA plasma with 15-fold greater potency than emicizumab^[1].
Mim8 exhibits procoagulant activity in hemophilia A-like blood that is ~13-fold more potent than a sequence identical analog of emicizumab, as measured by peak thrombin generation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mim8 demonstrates high subcutaneous bioavailability (97%) in cynomolgus monkeys^[1].
Denecimig (Mim8) (up to 3 mg/kg/wk; weekly; 26 weeks) reduces bleeding in cynomolgus monkey hemophilia A models and demonstrates potent pharmacodynamic effects and a favorable safety profile^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2158  [NCBI] & 2159  [NCBI]

P00740 & P00742

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.46 kDa

2488745-86-2

Liquid

Colorless to light yellow

[Denecimig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Stine L Kjellev, et al. Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo. Blood (2019) 134 (Supplement_1): 96.

  [2]. Lentz SR, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024;22(4):990-1000.  [Content Brief]